Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02079376
Other study ID # MC CP TAN2012-60
Secondary ID
Status Recruiting
Phase N/A
First received February 26, 2014
Last updated March 15, 2016
Start date November 2013
Est. completion date December 2016

Study information

Verified date March 2016
Source Metacure
Contact n/a
Is FDA regulated No
Health authority Poland: National Institute of Medicines
Study type Interventional

Clinical Trial Summary

Study to evaluate the efficacy of gastric stimulation (GCM) using the DIAMOND System in the improvement of glycemic control measured by changes in HbA1c.

Relationship between blood TG level and the GCM efficacy will be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Male and female subjects 18 through 70 years of age

- Body mass index > 30 and < 45 (kg/m2)

- Type 2 diabetes duration of at least 6 months

- Type 2 diabetic subjects treated with oral anti-diabetic agents [Sulfonylurea, Metformin, thiazolinedione (TZD) or DPP-4 inhibitors]

- Stable anti-diabetic medications for at least 3 months prior to enrollment, six months for thiazolinedione (TZD)

- The subject has been under routine diabetes care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment

- HbA1c 7.3% and = 9.5 % on Visit 1

- Stable HbA1c, defined as no significant change (variation = 0.5%) between a historical value recorded in the subject's medical record within 3 months prior to enrollment and the HbA1c gathered on Visit 1.

- Fasting blood glucose >120 and < 350 mg/dl on Visit 1.

- Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods

- Stable weight, defined as no significant weight change (variation <3%) within three months prior to enrollment as documented in the subject's medical record. For the subject treated with thiazolinedione, stable weight within six months.

- If taking theses medication, sable anti-hypertensive and lipid-lowering medication for at least one month prior to enrollment

- If subject is under anti-depressant medication the treatment needs to be stable for at least six months prior to enrollment.

- Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the DIAMOND System

- Willingness to perform at least four (3) capillary blood glucose tests per day twice a week for the duration of the study

- Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial

- Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial

- Able to provide voluntary informed consent

Exclusion Criteria:

- Insulin therapy in last 3 months

- Taking GLP-1 agonists or in the last 3 months before the enrollment

- Currently taking fibrates, nicotinamide and omega 3 fatty acids as antilipidemic treatment

- Subjects with an EF less than 35% or otherwise indicated for an ICD

- Taking medications known to affect gastric motility such as narcotics (chronic use) and anticholinergics/antispasmodics

- Experiencing severe and progressing diabetic complications (i.e. retinopathy not stabilized, nephropathy with macroalbuminuria)

- Prior wound healing problems due to staphylococcus or candida

- Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures

- Use of anti-psychotic medications

- Diagnosed with a eating disorder such as bulimia or binge eating

- Obesity due to an endocrine disorder (e.g. Cushing disease)

- Pregnant or lactating

- Diagnosed with impaired liver function (liver enzymes 3 times greater than normal)

- Any prior bariatric surgery

- Any history of pancreatitis

- Any history of peptic ulcer disease within 5 years of enrollment

- Diagnosed with gastroparesis

- Use of active medical devices (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implanted or worn). Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled.

- Cardiac history that physician feels should exclude the subject from the study.

- Use of another investigator device or agent in the 30 days prior to enrollment

- A history of life-threatening disease within 5 years of enrollment

- Change in diabetic medication from between Visit 1 and Visit 3.

- Any additional condition(s) that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
DIAMOND System
DIAMOND Implantable Pulse Generator (IPG)

Locations

Country Name City State
Australia Epworth Research Institute Richmond, Victoria
Austria Tilak Innsbruck Innsbruck
Greece "Attikon" Hospital AThens
Greece "Evgenidio " Hospital Athens
Italy Clinica Pineta Grande Rome
Italy The Università Cattolica del Sacro Cuore Rome
Poland Medical University Bialystok
Poland Medical University Bydgoszcz
Poland "Diabeta-Care" Lubin
Poland Medical University Szczecin
Poland Centre for Postgraduate Medical Education (CMKP) Warsaw
Serbia Klinika za digestivnu hirurgiju Belgrade
Serbia Institut za pluce bolesti Vojvodine Kamenica

Sponsors (1)

Lead Sponsor Collaborator
Metacure

Countries where clinical trial is conducted

Australia,  Austria,  Greece,  Italy,  Poland,  Serbia, 

Outcome

Type Measure Description Time frame Safety issue
Primary improvement of HbA1c improvement of glycemic control measured by changes in HbA1c 48 weeks No
Secondary Relationship between blood TG level and the GCM efficacy Relationship between blood TG level and the GCM efficacy 48 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A